Entrada Therapeutics, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.7M | $59.1M | $41.8M | $43.7M | $18.2M | $25.3M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $32.0M | $28.6M | $28.3M | $22.2M | $26.3M | $23.1M | $19.0M | $16.2M |
| SG&A Expense | $9.2M | $9.4M | $8.7M | $7.5M | $8.2M | $7.9M | $7.0M | $7.3M |
| Operating Income | $53.4M | $21.1M | $4.9M | $14.0M | $-16.3M | $-5.8M | $-25.9M | $-23.6M |
| Operating Margin | 56.4% | 35.7% | 11.7% | 32.0% | -89.7% | -22.9% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $2.8M | $1.8M | $18.7M | $-17.4M | $13.8M | $3.6M | $0 | $0 |
| Net Income | $55.0M | $23.5M | $-9.5M | $35.5M | $-25.9M | $-6.7M | $-25.1M | $-23.2M |
| Net Margin | 58.1% | 39.7% | -22.8% | 81.1% | -142.7% | -26.4% | — | — |
| EPS (Basic) | $1.61 | $0.70 | $-0.28 | $1.07 | $-0.78 | $-0.21 | $-0.16 | $-0.15 |
| EPS (Diluted) | $1.55 | $0.68 | $-0.23 | $1.02 | $-0.78 | $-0.21 | $-0.16 | $-0.15 |
| Shares Outstanding (Basic) | 34.2M | 33.5M | 33.1M | 33.3M | 33.2M | 32.4M | 156.5M | 156.4M |
| Shares Outstanding (Diluted) | 35.5M | 34.8M | 33.1M | 34.8M | 33.2M | 32.4M | 156.5M | 156.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |